By: IPP Bureau
Last updated : July 21, 2025 7:54 pm
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Biogen today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).
Since breaking ground in 1995, Biogen’s manufacturing in RTP has played a vital role in delivering the company’s pipeline and portfolio of innovative treatments for millions of patients around the world.
Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline.
In the next few years, Biogen plans to continue investing in multiple modalities and factories across the company’s two campuses in RTP. These investments will include further expansion of the antisense oligonucleotide (ASO) capabilities and infrastructure, establishing clinical and commercial multi-platform fill finish capabilities, and continuing to modernize manufacturing technologies and controls through further advanced automation and artificial intelligence.
“We are proud of our longstanding commitment to manufacturing innovation, investment, and collaboration with the Research Triangle Park community,” said Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen. “Our manufacturing footprint in the United States has played a critical role in Biogen’s history and success, and in advancing the treatments that are making an impact for patients, families, and communities here in the U.S. and around the world. With this investment, we will modernize and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.”